Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy

Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy

Abstract Mortality associated with pancreatic cancer is among the highest of all malignancies, with a 5-year overall survival of 5–10%. Immunotherapy, represented by the blocking antibodies against programmed cell death protein 1 or its ligand 1 (anti-PD-(L)1), has achieved remarkable success in a n...

Full description

Bibliographic Details
Main Authors: Lingyue Liu, Xing Huang, Fukang Shi, Jinyuan Song, Chengxiang Guo, Jiaqi Yang, Tingbo Liang, Xueli Bai
Format: Article
Language:English
Published: BMC 2022-02-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Pancreatic cancer
Immune checkpoint inhibitor
PD-1
PD-L1
Combinational therapy
Systematic treatment
Online Access:https://doi.org/10.1186/s13046-022-02273-w

Internet

https://doi.org/10.1186/s13046-022-02273-w

Similar Items